<DOC>
	<DOCNO>NCT01218399</DOCNO>
	<brief_summary>This investigator-initiated study Dr. Nadeau write protocol receive funding Astra Zeneca grant direct , perform , monitor study Stanford staff . We hypothesize budesonide/formoterol combination improve efficacy budesonide alone .</brief_summary>
	<brief_title>Use Symbicort Pulmicort Treat Viral-mediated Asthma Exacerbations</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Subjects consider inclusion study base meeting follow criterion : 1 . Male female , age 12 65 year 2 . Subjects mild moderate asthma determine NHLBI 2007 guideline 3 . Subjects exacerbation asthma symptom NHLBI 2007 guideline 4 . IgE level study entry le 50 IU/mL 5 . Men woman reproductive potential document use adequate contraception study 3 month conclusion treatment study drug/placebo 6 . Historical documentation asthma patient 's medical record . The patient 6 month asthma medication management Stanford physician . 7 . Women childbearing potential negative pregnancy test ( urine serum ) time study entry 8 . Subject 's guardian capable understanding purpose risk study sign statement inform consent study Subjects ineligible study base one follow criterion : 1 . With chronic acute disease might interfere evaluation Symbicort Pulmicort Flexhaler therapy 2 . Pregnancy lactation 3 . Current prior malignancy ( exclude nonmelanoma skin carcinoma carcinoma situ cervix adequately treat ) 4 . History infection human immunodeficiency virus ( HSC1 ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) ; Hepatitis A virus ( HAV ) 5 . Infections require intravenous antibiotic therapy 6 . Significant organ dysfunction , include cardiac , renal , liver , CNS , pulmonary , vascular , gastrointestinal , endocrine , metabolic ( e.g. , creatinine &gt; 1.6 mg/dL ; ALT AST &gt; 1.5x upper limit normal ; history myocardial infarction , congestive heart failure , arrhythmia within 6 month prior study entry ) 7 . Treatment humanize chimeric antibody therapy within 4 week prior study entry 8 . Treatment investigational drug therapy within 2 week prior study entry 9 . Any use oral , systemic corticosteroid within 2 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Asthma</keyword>
</DOC>